NHI:NYE-National Health Investors Inc (USD)

COMMON STOCK | REIT - Healthcare Facilities |

Last Closing

USD 76.54

Change

+2.01 (+2.70)%

Market Cap

USD 3.54B

Volume

0.24M

Analyst Target

USD 61.22
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent living, assisted living and memory care communities, entrance-fee retirement communities, skilled nursing facilities, and specialty hospitals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-22 )

Largest Industry Peers for REIT - Healthcare Facilities

Symbol Name Price(Change) Market Cap
WELL Welltower Inc

+3.60 (+2.51%)

USD 92.95B
VTR Ventas Inc

+1.48 (+2.22%)

USD 29.73B
DOC Healthpeak Properties Inc

+0.36 (+1.95%)

USD 13.10B
CTRE CareTrust REIT Inc.

+0.47 (+1.67%)

USD 5.43B
AHR American Healthcare REIT, Inc.

+0.59 (+1.99%)

USD 4.79B
LTC LTC Properties Inc

+0.55 (+1.55%)

USD 1.55B
DHC Diversified Healthcare Trust

+0.03 (+1.35%)

USD 0.60B
UHT Universal Health Realty Income..

+0.95 (+2.49%)

USD 0.58B
CHCT Community Healthcare Trust Inc

N/A

USD 0.45B
GMRE-PA Global Medical REIT Inc

+0.33 (+1.33%)

USD 0.40B

ETFs Containing NHI

DIV Global X SuperDividend U... 2.42 % 0.46 %

+0.29 (+1.67%)

USD 0.62B

Market Performance

  Market Performance vs. Industry/Classification (REIT - Healthcare Facilities) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.45% 81% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.45% 81% B- 91% A-
Trailing 12 Months  
Capital Gain 22.00% 69% C- 90% A-
Dividend Return 4.30% 31% F 67% D+
Total Return 26.30% 69% C- 91% A-
Trailing 5 Years  
Capital Gain 52.29% 79% B- 58% F
Dividend Return 35.64% 57% F 77% C+
Total Return 87.93% 79% B- 64% D
Average Annual (5 Year Horizon)  
Capital Gain 5.36% 60% D- 55% F
Dividend Return 11.45% 60% D- 66% D+
Total Return 6.08% 67% D+ 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 21.98% 53% F 46% F
Risk Adjusted Return 52.07% 60% D- 67% D+
Market Capitalization 3.54B 55% F 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector